Filter Specialty
Filterspecialty
Submit To The Journals
Previous
Insight
Next
Insight

Hyperprogressive Disease in Patients with Advanced Non-small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Authors: Katrina Mountfort, Senior Medical Writer, Touch Medical Media, Reading, UK

    The treatment landscape of many cancers has been transformed by the emergence of immune checkpoint inhibitors targeting programmed cell death 1 (PD-1) and its ligand (PD-L1). These agents are capable of eliciting durable responses and are particularly important in the treatment of non-small cell lung cancer (NSCLC), which is associated with a poor prognosis. However, recent data suggest that PD-1/PD-L1 blockade can lead to hyperprogressive disease (HPD), resulting in a promotion of tumour growth.1–3

    Although accelerated progression has been reported for some time, many experts did not believe that it was genuinely related to immune checkpoint inhibition. In several phase III studies, Kaplan–Meier survival curves have shown that immunotherapy initially appears to be worse than chemotherapy, then the curves cross and immunotherapy proves superior.4,5 Some observed accelerations in tumour growth following immune checkpoint blockade are temporary, known as pseudoprogression, and has been reported in 0.6–5.8% of cases and caused by initial radiographic progression from immune cell infiltration around the tumour.6 By contract, hyperprogression involves a drastic and irreversible progression of disease, reducing patient quality of life and becoming life-threatening, with rates of 9–29% reported to date.1–3 Hyperprogression is often defined as ≥2-fold increase in the tumour growth ratio or tumour growth kinetics ratio during treatment with immune checkpoint inhibitors compared with that observed prior to treatment.3

    This evidence was supported by a presentation at the 2019 World Conference on Lung Cancer (WCLC), which was held on 7–10 September 2019 in Barcelona, Spain, and hosted by the International Association for the Study of Lung Cancer (IASLC), A retrospective study involved 257 patients with advanced NSCLC who were treated between April 2013 and December 2019 at the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano in Italy. Patients had received at least one cycle of immune checkpoint inhibitors and were stratified by four categories: responders (57 cases, 22.2%), best response stable disease (69 cases, 26.8%), best response progressive disease (78 cases, 30.4%), or hyperprogressive disease (53 cases, 20.6%), defined as in a previous study.2 At a median follow-up of 23.5 months, the median progression-free survival was 14.2, 6.5, 2.3, and 1.5 months (p<0.0001) and median overall survival was 32.5, 17.8, 7.8, and 4.1 months (p<0.00001) in the responders, stable disease, progressive disease, and hyperprogressive disease groups, respectively. After adjusting for variables between the patients in the progressive disease and hyperprogressive disease groups, patients in the hyperprogressive disease group were found to have worse clinical outcomes than those in the progressive disease group, suggesting that regular progression was different than hyperprogression.7

    Hyperprogression is clearly an unusual response to immune checkpoint inhibitor therapy, and it is therefore important to identify the minority of patients who are likely to experience it. Studies to date indicate that hyperprogression is not associated with higher tumour burden at baseline, the number of previous lines of treatment, or the expression of PD-L1 in tumours.3 Three clinical factors – older age,3  the presence of more than two metastatic sites prior to the administration of PD-1/PD-L1 inhibitors,1 and regional recurrence in an irradiated field in cases of head and neck squamous cell carcinoma8 – have been associated with hyperprogression. However, these findings have not been consistently reposted across studies. In terms of genetic alterations, MDM2/MDM4 amplification, and EGFR mutations have been shown to be associated with hyperprogression.8,9

    More research needed to fully characterise this phenomenon as studies to date have been relatively small. Since PD-1 and PD-L1 inhibitors are now approved in many countries around the world, a global retrospective study is warranted. There is also a need for a standardised definition of hyperprogression, as this varies across studies. It is possible that the use of chemotherapy in combination with PD-1/PD-L1 inhibitors may minimise the incidence of hyperprogression. In KEYNOTE-189, which compared the treatment of combined pembrolizumab/immunotherapy versus patients treated with pembrolizumab alone, both in the first-line setting, the crossing of the Kaplan–Meier curves was not seen.10

    Most urgently, it is important to promptly identify hyperprogression. Biopsies taken from patients with pseudoprogression have shown infiltration of inflammatory cells,11 which may be useful in distinguishing pseudoprogression form hyperprogression. Currently, there are no standard second-line systemic treatment options for patients who undergo progression on PD-1/PD-L1 inhibitors. National Comprehensive Cancer Network guidelines suggest treatment with chemotherapy alone or in combination with antiangiogenic agents as well as clinical trials.12 However, there have been no studies determining the optimum treatment for this scenario.

    In conclusion, PD-1/PD-L1 inhibitors are a major therapeutic advance, but they are not effective in everyone, and may be harmful in some. To optimise the use of these powerful agents, we need to identify those who will benefit most from them without the risk of hyperprogression.

     

    References

    1. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4:1543–52.
    2. Lo Russo G, Moro M, Sommariva M, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019;25:989–99.
    3. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23:1920–8.
    4. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
    5. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30.
    6. Wang Q, Gao J, Wu X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 2018;58:125–35.
    7. Lo Russo G, Signorelli D, Proto C, et al. Hyperprogressive disease in advanced non–small cell lung cancer patients treated with immune checkpoint inhibitors. Presented at: IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer, Barcelona Spain, 7–10 September 2019.
    8. Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242–50.
    9. Ingavi AK, Menon S, Kilari D, et al. Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs). Ann Oncol. 2017;28:1140PD.
    10. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.
    11. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.
    12. National Comprehensive Cancer Network. Non-small cell lung cancer, 2019. Available at: www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed 16 September 2019).

     

  • Touch Medical Media Limited, trading as Touch Medical Media, is a private limited company registered in England and Wales at The White House, Mill Road, Goring, Reading, England, RG8 9DD with registered number 08197142. © 2019 All rights reserved.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.